David Gandara: Clinical and Biological Implications of Plasma Proteomics in NSCLC Presented at AACR 2025
David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post on X:
“We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC.
At AACR 2025 we present the biological rationale and function of these proteins. Potential broad therapeutic implications.”
Title: Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Authors: Petros Christopoulos, Michal Harel, Kimberly McGregor, Yehuda Brody, Igor Puzanov, Jair Bar, Yehonatan Elon, Itamar Sela, Ben Yellin, Coren Lahav, Shani Raveh, Anat Reiner-Benaim, Niels Reinmuth, Hovav Nechushtan, David Farrugia, Ernesto Bustinza-Linares, Yanyan Lou, Raya Leibowitz, Iris Kamer, Alona Zer Kuch, Mor Moskovitz, Adva Levy-Barda, Ina Koch, Michal Lotem, Rivka Katzenelson, Abed Agbarya, Gillian Price, Helen Cheley, Mahmoud Abu-Amna, Tom Geldart, Maya Gottfried, Ella Tepper, Andreas Polychronis, Ido Wolf, Adam P. Dicker, David P. Carbone, David R. Gandara
Abstract 2058: Clinical and biological implications of plasma proteomic patterns in NSCLC patients treated with immune checkpoint inhibitors
Authors: Michal Harel, Nili Dahan, Coren Lahav, Eyal Jacob, Yehonatan Elon, Igor Puzanov, Ronan J. Kelly, Yuval Shaked, Raya Leibowitz, David P. Carbone, David R. Gandara, Adam P. Dicker
More posts featuring AACR 2025 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023